TP53 and posterior cortical atrophy: Herein, we further distilled TP53 genetic alterations utilizing the TCGA (Cancer Genome Atlas) database and found that approximately 46% of primary PCa patients exhibit TP53 alterations, including loss of heterozygosity (29%), mutations (12.2%), homozygous deletion (homodeletion; 4%), and fusion (1.2%) (Figure 1B).